Nkarta, Inc. (NKTX)
After hours:
| Previous Close | 7.49 |
| Open | 7.63 |
| Bid | 7.47 x 100 |
| Ask | 7.63 x 100 |
| Day's Range | 7.25 - 7.77 |
| 52 Week Range | 1.28 - 16.24 |
| Volume | |
| Avg. Volume | 994,040 |
| Market Cap | 530.621M |
| Beta (5Y Monthly) | 0.71 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.40 |
| Earnings Date | May 09, 2024 - May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 19.25 |
GlobeNewswireNkarta to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in two upcoming investor conferences: Needham Virtual Healthcare ConferenceApril 9, 20241:30 p.m. ET – fireside chat Canaccord Genuity Horizons in Oncology Virtual ConferenceApril 15, 20241:00 p.m. ET – panel discussion A simultaneous webcast of each event will be available on the Inves
Investor's Business DailyWhy Nkarta Stock Just Boomeranged Following A Massive Dive On Friday
Nkarta stock surged Monday — partially reversing a 31% dive on Friday — after unveiling promising test results for its lymphoma treatment.
- GlobeNewswire
Nkarta Announces Pricing of $240 Million Underwritten Offering
SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced the pricing of an underwritten offering of 21,010,000 shares of its common stock at a price of $10.00 per share and pre-funded warrants to purchase 3,000,031 shares of common stock. The pre-funded warrants are being sold at a price of $9.9999 per warrant, which represents the per share offering price for
